Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3 …
…, Y Hamamoto, Y Doki, CC Yen, Y Kubota… - The Lancet …, 2019 - thelancet.com
Background Chemotherapy for patients with advanced oesophageal squamous cell carcinoma
offers poor long-term survival prospects. We report the final analysis from our study of the …
offers poor long-term survival prospects. We report the final analysis from our study of the …
[HTML][HTML] Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
K Fujita, Y Kubota, H Ishida, Y Sasaki - World journal of …, 2015 - ncbi.nlm.nih.gov
Irinotecan hydrochloride is a camptothecin derivative that exerts antitumor activity against a
variety of tumors. SN-38 produced in the body by carboxylesterase is the active metabolite of …
variety of tumors. SN-38 produced in the body by carboxylesterase is the active metabolite of …
[HTML][HTML] Efficacy of endoscopic resection and selective chemoradiotherapy for stage I esophageal squamous cell carcinoma
…, H Doyama, T Oyama, H Nebiki, K Amagai, Y Kubota… - Gastroenterology, 2019 - Elsevier
Background & Aims Esophagectomy is the standard treatment for stage I esophageal
squamous cell carcinoma (ESCC). We conducted a single-arm prospective study to confirm the …
squamous cell carcinoma (ESCC). We conducted a single-arm prospective study to confirm the …
Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma …
…, MJ Ahn, Y Hamamoto, Y Doki, CC Yen, Y Kubota… - Clinical Cancer …, 2022 - AACR
Purpose: Limited long-term data are available on immune checkpoint inhibitor use in patients
with advanced esophageal squamous cell carcinoma (ESCC). We report 3-year follow-up …
with advanced esophageal squamous cell carcinoma (ESCC). We report 3-year follow-up …
Long-term stable disease in a rectal-cancer patient treated by methionine restriction with oral recombinant methioninase and a low-methionine diet
Y Kubota, Q Han, K Hamada, Y Aoki… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: Rectal cancer is a recalcitrant disease with limited treatment options. Pre-clinical
studies have shown the efficacy of methionine restriction with a low-methionine diet …
studies have shown the efficacy of methionine restriction with a low-methionine diet …
[HTML][HTML] Reversion of methionine addiction of osteosarcoma cells to methionine independence results in loss of malignancy, modulation of the epithelial-mesenchymal …
Y Aoki, Q Han, Y Tome, J Yamamoto, Y Kubota… - Frontiers in …, 2022 - frontiersin.org
Methionine addiction, a fundamental and general hallmark of cancer, known as the Hoffman
Effect, is due to altered use of methionine for increased and aberrant transmethylation …
Effect, is due to altered use of methionine for increased and aberrant transmethylation …
Plasma levels of soluble PD-L1 correlate with tumor regression in patients with lung and gastric cancer treated with immune checkpoint inhibitors
…, R Ohkuma, M Shida, R Onoue, Y Kubota… - Anticancer …, 2019 - ar.iiarjournals.org
Background/Aim: Cancer immune therapy by immune checkpoint inhibitors (ICIs) is a promising
therapeutic strategy for various cancer types. Among ICIs, anti-programmed cell death …
therapeutic strategy for various cancer types. Among ICIs, anti-programmed cell death …
[HTML][HTML] Synergy of combining methionine restriction and chemotherapy: the disruptive next generation of cancer treatment
Y Kubota, Q Han, Y Aoki, N Masaki… - Cancer Diagnosis & …, 2023 - ncbi.nlm.nih.gov
All cancer cell types are methionine-addicted, which is termed the Hoffman effect. Cancer
cells, unlike normal cells, cannot survive without large amount of methionine. In general, when …
cells, unlike normal cells, cannot survive without large amount of methionine. In general, when …
[HTML][HTML] First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup …
…, Y Shirakawa, M Okada, R Ishihara, Y Kubota… - Esophagus, 2023 - Springer
Background Programmed cell death 1 (PD-1)-based treatments are approved for several
cancers. CheckMate 648, a global, phase 3 trial, showed that first-line nivolumab (anti-PD-1 …
cancers. CheckMate 648, a global, phase 3 trial, showed that first-line nivolumab (anti-PD-1 …
[HTML][HTML] Superiority of [11C]methionine over [18F]deoxyglucose for PET Imaging of Multiple Cancer Types Due to the Methionine Addiction of Cancer
Y Kubota, T Sato, C Hozumi, Q Han, Y Aoki… - International Journal of …, 2023 - mdpi.com
Positron emission tomography (PET) is widely used to detect cancers. The usual isotope for
PET imaging of cancer is [ 18 F]deoxyglucose. The premise of using [ 18 F]deoxyglucose is …
PET imaging of cancer is [ 18 F]deoxyglucose. The premise of using [ 18 F]deoxyglucose is …